SCHEMBL24537124

SCHEMBL24537124

Cc1cn(COCC[Si](C)(C)C)nc1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 1/20 0.39
KLKB1 P03952 2/20 0.37
NPC1 O15118 1/20 0.33
DGAT1 O75907 6/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 2/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16559346 0.90 KLKB1 (0.36) PTGER1KLKB1NPC1DGAT1KDM4E
SCHEMBL24537118 0.87 NPC1 (0.40) KLKB1NPC1DGAT1KDM4E
SCHEMBL24537117 0.85 ALDH1A1 (0.40) NPC1DGAT1KDM4EMAPT
SCHEMBL30630545 0.84 NPC1 (0.41) PTGER1KLKB1NPC1DGAT1KDM4E
SCHEMBL29601443 0.83 KMT2A (0.39) PTGER1KLKB1NPC1DGAT1MEN1
SCHEMBL15555261 0.83 KMT2A (0.36) KLKB1NPC1DGAT1KDM4EMEN1
SCHEMBL16445794 0.81 POLB (0.33) PTGER1KLKB1NPC1DGAT1
SCHEMBL28851116 0.80 PTGER1 (0.39) PTGER1KDM4EMAPTMEN1USP2
SCHEMBL4016651 0.80 ALDH1A1 (0.43) NPC1MAPTMEN1HPGDKMT2A
SCHEMBL20028437 0.80 NPC1 (0.37) NPC1DGAT1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 EP disclosed
CN-116829151-A Azaquinazoline pan KRAS inhibitors 米拉蒂治疗股份有限公司 2023-09-29 CN disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 WO disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 WO disclosed